drugset / Trial / NCT01581593
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Kedrion IVIG 10% (an immunoglobulin solution) is effective in treating Primary Immunodeficiency (PID).
Timeline
- Start
- 2012-11-12
- Primary completion
- 2014-08-27
- Completion
- 2014-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Kedrion IVIG 10% | Protein / enzyme biologic | 300 mg/kg | Intravenous |
| Subject | Kedrion IVIG 10% | Protein / enzyme biologic | 900 mg/kg | Intravenous |